{"id":673649,"date":"2023-10-24T18:40:01","date_gmt":"2023-10-24T18:40:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=673649"},"modified":"2023-10-24T18:40:01","modified_gmt":"2023-10-24T18:40:01","slug":"triple-negative-breast-cancer-tnbc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-merck-roche-tesaro-clovis-gilead","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/triple-negative-breast-cancer-tnbc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-merck-roche-tesaro-clovis-gilead_673649.html","title":{"rendered":"Triple Negative Breast Cancer (TNBC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Merck, Roche, Tesaro, Clovis, Gilead"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Triple Negative Breast Cancer (TNBC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Merck, Roche, Tesaro, Clovis, Gilead\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Triple Negative Breast Cancer (TNBC) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Merck, Roche, Tesaro, Clovis, Gilead\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 80+ pipeline drugs in the Triple Negative Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Triple Negative Breast Cancer (TNBC) Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Triple Negative Breast Cancer Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and Triple Negative Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Triple Negative Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Triple Negative Breast Cancer (TNBC) Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Triple Negative Breast Cancer treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Triple Negative Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Triple Negative Breast Cancer companies involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Triple Negative Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Triple Negative Breast Cancer therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/3b1323bde76195f7a92a69a3d2bb9286.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer (TNBC) Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Currently, the treatment paradigm for TNBC includes a few treatment options, such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery, and radiation.&nbsp; The Triple Negative Breast Cancer market holds few US FDA-approved drugs, such as KEYTRUDA (pembrolizumab) by Merck Sharpe and Dohme, LYNPARZA (olaparib) by AstraZeneca, TRODELVY (sacituzumab govitecan) by Gilead Sciences, etc. However, various off-label drugs are used for treating TNBC, which include Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">TNBC is a type of breast cancer that does not express the estrogen and the progesterone receptors and the human epidermal growth factor receptor type 2 (HER2). Since there are no positive markers to reliably classify TNBC, these tumors are not yet treated with targeted therapies. Perhaps for this reason, they are the most aggressive form of breast carcinomas. The treatment paradigm for TNBC generally includes a combination of conventional therapies such as surgery, radiation, and chemotherapy.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Currently, the therapeutic market of TNBC accounts mainly for the systemic chemotherapies (either alone or in combination), such as Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc. These chemotherapies are being used off-label, as both first-line and second-line treatment of TNBC patients, with variations in the dosing frequency and drug combinations.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. <strong>75+ key companies developing therapies for Triple Negative Breast Cancer<\/strong>. Currently, <strong>Jiangsu HengRui Medicine<\/strong> is leading the therapeutics market with its Triple Negative Breast Cancer drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Triple Negative Breast Cancer (TNBC) Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Astellas<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CytoDyn<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gilead Science<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HiberCell<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomedics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imprime PGG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Infinity Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tesaro<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Triple Negative Breast Cancer (TNBC) Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Atezolizumab: Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Capitasertib: AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cobimetinib: Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Enzalutamide: Pfizer\/Astellas<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HiberCell: Imprime PGG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ipatasertib: Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IPI-549 (Eganelisib): Infinity Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KEYTRUDA (pembrolizumab): Merck &amp; Co<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Niraparib: Tesaro<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pembrolizumab: Merck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rucaparib: Clovis Oncology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sacituzumab Govitecan: Immunomedics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TRODELVY (sacituzumab govitecan-hziy): Gilead Sciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HiberCell: Imprime PGG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MDNA11: Medicenna Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leronlimab (PRO 140): CytoDyn<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Triple Negative Breast Cancer Companies Working in the Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Triple Negative Breast Cancer Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers the emerging products under different phases of clinical development like &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Triple Negative Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Triple Negative Breast Cancer Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Triple Negative Breast Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Triple Negative Breast Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Triple Negative Breast Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Triple Negative Breast Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Triple Negative Breast Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Triple Negative Breast Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Triple Negative Breast Cancer Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Triple Negative Breast Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Triple Negative Breast Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Triple Negative Breast Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Triple Negative Breast Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/triple-negative-breast-cancer-tnbc-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/optic-neuropathy-market\">Optic Neuropathy Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Optic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032&#8221; report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Optic Neuropathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Optic Neuropathy market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=triple-negative-breast-cancer-tnbc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-merck-roche-tesaro-clovis-gilead\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/market-research\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/market-research<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/market-research\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=triple-negative-breast-cancer-tnbc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-merck-roche-tesaro-clovis-gilead\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 75+ key pharma and biotech companies are working on 80+ pipeline drugs in the Triple Negative Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/triple-negative-breast-cancer-tnbc-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-merck-roche-tesaro-clovis-gilead_673649.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-673649","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/673649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=673649"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/673649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=673649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=673649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=673649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}